DE69434209D1 - REGULATION DER GENEXPRESSION VON bcl-2 - Google Patents

REGULATION DER GENEXPRESSION VON bcl-2

Info

Publication number
DE69434209D1
DE69434209D1 DE69434209T DE69434209T DE69434209D1 DE 69434209 D1 DE69434209 D1 DE 69434209D1 DE 69434209 T DE69434209 T DE 69434209T DE 69434209 T DE69434209 T DE 69434209T DE 69434209 D1 DE69434209 D1 DE 69434209D1
Authority
DE
Germany
Prior art keywords
bcl
regulation
gene expression
gene
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434209T
Other languages
English (en)
Inventor
John C Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of DE69434209D1 publication Critical patent/DE69434209D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE69434209T 1993-09-20 1994-09-20 REGULATION DER GENEXPRESSION VON bcl-2 Expired - Lifetime DE69434209D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12425693A 1993-09-20 1993-09-20
PCT/US1994/010725 WO1995008350A1 (en) 1993-09-20 1994-09-20 REGULATION OF bcl-2 GENE EXPRESSION

Publications (1)

Publication Number Publication Date
DE69434209D1 true DE69434209D1 (de) 2005-02-03

Family

ID=22413765

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435218T Expired - Lifetime DE69435218D1 (de) 1993-09-20 1994-09-20 Regulation der Genexpression von bcl-2
DE69434209T Expired - Lifetime DE69434209D1 (de) 1993-09-20 1994-09-20 REGULATION DER GENEXPRESSION VON bcl-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69435218T Expired - Lifetime DE69435218D1 (de) 1993-09-20 1994-09-20 Regulation der Genexpression von bcl-2

Country Status (9)

Country Link
EP (2) EP1584682B1 (de)
JP (6) JP2001505401A (de)
AT (1) ATE286125T1 (de)
CA (1) CA2172153C (de)
DE (2) DE69435218D1 (de)
DK (1) DK1584682T3 (de)
ES (1) ES2326118T3 (de)
PT (1) PT1584682E (de)
WO (1) WO1995008350A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0941124A4 (de) * 1996-11-21 2004-12-15 Univ Nebraska Antisense-oligonukleotid zusammenstellungen zur gezielten tötung von krebszellen
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
JP4187413B2 (ja) 1998-03-20 2008-11-26 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション 遺伝子発現の制御
WO2000001393A2 (en) * 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
GB9910119D0 (en) * 1999-04-30 1999-06-30 Novartis Ag Organic compounds
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1640452A4 (de) 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd Die expression von bcl-2 hemmende doppelstrang-oligo-rna und diese enthaltende pharmazeutische zusammensetzung
AU2004303464B2 (en) 2003-12-23 2009-10-01 Santaris Pharma A/S Oligomeric compounds for the modulation of BCL-2
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
JP5623016B2 (ja) * 2005-12-01 2014-11-12 プロネイ・セラピューティクス・インコーポレイテッドＰｒｏｎａｉｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌治療法およびそれに用いる医薬組成物
EP1957044B1 (de) 2005-12-01 2013-03-13 Pronai Therapeutics, Inc. Amphotere liposomen
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
JP2016509572A (ja) * 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
EP0590090A4 (de) * 1991-06-18 1995-04-12 Univ Temple Selektive hemmung leukämischer zellproliferation durch -i(bcr-abl) antisens-oligonukleotide.
WO1993020200A1 (en) * 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment

Also Published As

Publication number Publication date
JP4057848B2 (ja) 2008-03-05
EP0722342B1 (de) 2004-12-29
WO1995008350A1 (en) 1995-03-30
ES2326118T3 (es) 2009-10-01
PT1584682E (pt) 2009-08-03
JP2010184933A (ja) 2010-08-26
JP2003026609A (ja) 2003-01-29
EP1584682B1 (de) 2009-07-15
CA2172153C (en) 2010-03-09
JP2009029812A (ja) 2009-02-12
DK1584682T3 (da) 2009-09-21
EP0722342A4 (de) 1999-01-07
EP0722342A1 (de) 1996-07-24
DE69435218D1 (de) 2009-08-27
JP2006182651A (ja) 2006-07-13
ATE286125T1 (de) 2005-01-15
JP2001505401A (ja) 2001-04-24
EP1584682A1 (de) 2005-10-12
CA2172153A1 (en) 1995-03-30
JP2006257092A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE286125T1 (de) Regulation der genexpression von bcl-2
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
ATE215125T1 (de) ßHEAT SHOCKß-PROTEINE UND BEHANDLUNG VON TUMOREN
DE69230043D1 (de) Materialien und methoden zur schädlingsbekämpfung
ATE163046T1 (de) Genetische veränderung von endothelzellen
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
EP0948522A4 (de) Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren
DE69227392D1 (de) Serumfreies Medium zur Züchtung von Tierzellen
AU3869793A (en) 7 beta-substituted-4-aza-5 alpha-cholestan-3-ones as 5 alpha-reductase inhibitors
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE3767470D1 (de) System zum regeln der von mehreren kathoden einer ionenquelle ausgehenden stroeme und ionenantrieb.
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69320246D1 (de) Hardware-Verschlüsselungsschaltung unter Verwendung von mehreren linearen Transformationsausführungen
DE69405546D1 (de) Lineare mikrowellenquelle zur plasmabehandlung von flächen.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DE69313316D1 (de) Verwendung von Oxazopyrrolochinolinen und Pyrrolochinolonchinonen zur Herstellung von Produktionsbeschleunigern von Nervenwachstumsfaktoren g
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
DE69016693D1 (de) Züchtung von transformierten Mikroorganismen.
PT733370E (pt) Utilizacao da sequencia de um promotor genico para o tratamento de doencas reumaticas
DE59307112D1 (de) Verwendung von Polyorganosiloxan-Pfropfprodukten zur Lederzurichtung
DE59006435D1 (de) Monofunktionelle Polyacrylate, ihre Herstellung und Verwendung zur Herstellung von Polycarbonaten.
FI883135A (fi) Homocyklostatin och cyklostatin innehaollande polypeptider som antihypertensiva medel.
DK189285D0 (da) (6,11-dihydro-11-oxodibenz(b,e)oxepinyl)-pentancarboxylsyrer, deres fremstilling og anvendelse
DE68920803D1 (de) Stabilisierung und Verringerung der Hintergrund-Fluoreszenz von Hydroxy-cumarin-ester Enzymsubstraten.

Legal Events

Date Code Title Description
8332 No legal effect for de